Docking studies on αvβ3 integrin ligands:: Pharmacophore refinement and implications for drug design

被引:115
作者
Marinelli, L
Lavecchia, A
Gottschalk, KE
Novellino, E
Kessler, H
机构
[1] Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany
[2] Univ Naples Federico II, Dipartimento Chim Farmaceut & Tossicol, I-80131 Naples, Italy
关键词
D O I
10.1021/jm020577m
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Starting from the first crystal structure of the extracellular segment of the alpha(v)beta(3) integrin receptor with a cyclic RGD ligand bound to the active site, structural models for the interactions of known ligands with the 003 integrin receptor were generated by automated computational docking. The obtained complexes were evaluated for their consistency with structure-activity relationships and site-directed mutagenesis data. A comparison between the calculated interaction free energies and the experimental biological activities was also made. All the possible interactions of the investigated compounds at the active site and the probable ligand binding conformations provide an improved basis for structure-based rational ligand design. Additionally, our docking results allow a further validation and refinement of the pharmacophore model previously postulated by us.
引用
收藏
页码:4393 / 4404
页数:12
相关论文
共 80 条
[11]   APPROACH TO DISCOVERING NOVEL THERAPEUTIC AGENTS FOR OSTEOPOROSIS BASED ON INTEGRIN RECEPTOR BLOCKADE [J].
CHOREV, M ;
DRESNERPOLLAK, R ;
ESHEL, Y ;
ROSENBLATT, M .
BIOPOLYMERS, 1995, 37 (06) :367-375
[12]   The role of αvβ3 in prostate cancer progression [J].
Cooper, CR ;
Chay, CH ;
Pienta, KJ .
NEOPLASIA, 2002, 4 (03) :191-194
[13]   Antibody to beta(3) integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat [J].
Crippes, BA ;
Engleman, VW ;
Settle, SL ;
Delarco, J ;
Ornberg, RL ;
Helfrich, MH ;
Horton, MA ;
Nickols, GA .
ENDOCRINOLOGY, 1996, 137 (03) :918-924
[14]   N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists [J].
Dechantsreiter, MA ;
Planker, E ;
Mathä, B ;
Lohof, E ;
Hölzemann, G ;
Jonczyk, A ;
Goodman, SL ;
Kessler, H .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (16) :3033-3040
[15]   THE DEVELOPMENT AND USE OF QUANTUM-MECHANICAL MOLECULAR-MODELS .76. AM1 - A NEW GENERAL-PURPOSE QUANTUM-MECHANICAL MOLECULAR-MODEL [J].
DEWAR, MJS ;
ZOEBISCH, EG ;
HEALY, EF ;
STEWART, JJP .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1985, 107 (13) :3902-3909
[16]   ARGINYL-GLYCYL-ASPARTIC ACID (RGD) - A CELL-ADHESION MOTIF [J].
DSOUZA, SE ;
GINSBERG, MH ;
PLOW, EF .
TRENDS IN BIOCHEMICAL SCIENCES, 1991, 16 (07) :246-250
[17]   Nonpeptide αvβ3 antagonists.: 1.: Transformation of a potent, integrin-selective αIIbβ3 antagonist into a potent αvβ3 antagonist [J].
Duggan, ME ;
Duong, LT ;
Fisher, JE ;
Hamill, TG ;
Hoffman, WF ;
Huff, JR ;
Ihle, NC ;
Leu, CT ;
Nagy, RM ;
Perkins, JJ ;
Rodan, SB ;
Wesolowski, G ;
Whitman, DB ;
Zartman, AE ;
Rodan, GA ;
Hartman, GD .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (20) :3736-3745
[18]  
EBLE JA, 1997, INTEGRIN LIGAND INTE, P1
[19]   A peptidomimetic antagonist of the alpha(v)beta(3) integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo [J].
Engelman, VW ;
Nickols, GA ;
Ross, FP ;
Horton, MA ;
Griggs, DW ;
Settle, SL ;
Ruminski, PG ;
Teitelbaum, SL .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (09) :2284-2292
[20]   Binding model for nonpeptide antagonists of αvβ3 integrin [J].
Feuston, BP ;
Culberson, JC ;
Duggan, ME ;
Hartman, GD ;
Leu, CT ;
Rodan, SB .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (26) :5640-5648